Recently, the introduction of Cyclin-dependent kinase4/6 (CDK4/6) inhibitors in the treatment strategy for breast cancer achieved great success, particularly in breast cancer patients with positive hormonal receptors. The gene discussed is NR4A1; the disease is breast carcinoma.